Drug discovery targeting Na v 1.8: Structural insights and therapeutic potential.

Voltage-gated sodium (Na _v ) channels are crucial in transmitting action potentials in neurons. The tetrodotoxin-resistant subtype Na _v 1.8 is predominantly expressed in the peripheral nervous system, offering a unique opportunity to design selective inhibitors for pain relief. A number of compounds have been reported to specifically block Na _v 1.8. Among these, VX-548 is already in regulatory review for the treatment of moderate-to-severe acute pain and holds the promise to be the first non-opioid pain killer over the past twenty years. Recent structural studies using cryogenic electron microscopy (cryo-EM) and structure-based predictive modeling have provided unprecedented insights into the structural pharmacology of Na _v 1.8. In this review, we summarize the latest developments in Na _v 1.8-selective inhibitors, focusing on the druggable sites and mechanisms that confer subtype specificity. These structural insights highlight the potential for Na _v 1.8 inhibitors to deliver non-addictive pain management, thus illuminating the avenue to next-generation analgesic development.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 Elsevier Ltd. All rights reserved.)